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Abstract: Due to the usually late diagnosis and lack of effective therapies, hepatocellular carcinoma
(HCC), which poses a growing global health problem, is characterized by a poor prognosis.
Angiogenesis plays an important role in HCC progression, and vascular endothelial growth factor
(VEGF) and angiopoietins (Angs) are key drivers of HCC angiogenesis. VEGF-targeting strategies
already represent an important component of today’s systemic treatment landscape of HCC, whereas
targeting the Ang/Tie2 signaling pathway may harbor future potential in this context due to reported
beneficial anticancer effects when targeting this pathway. In addition, a better understanding of
the relation between Angs and HCC angiogenesis and progression may reveal their potential as
predictive factors for post-treatment disease progression and prognosis. In this review, we give a
comprehensive overview of the complex role of Ang/Tie2 signaling in HCC, pinpointing its potential
value as biomarker and target for HCC treatments, aiding HCC diagnosis and therapy.
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1. Hepatocellular Carcinoma
As the sixth-most commonly diagnosed type of cancer and the fastest-rising cause of cancer-related
mortality worldwide, hepatocellular carcinoma (HCC), the main primary liver cancer, poses a major
global health problem [1]. HCC usually occurs in the setting of chronic liver disease, characterized by
chronic hepatic inflammation and fibrosis, and is mainly caused by chronic viral hepatitis, persistent
alcohol abuse or metabolic syndrome [2,3]. Due to the worldwide increasing incidences of alcoholic
liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD), the burden of HCC is still rising [4–6].
HCC is an aggressive cancer with a poor prognosis, as it is often diagnosed at an advanced stage,
whereas potential curative interventions, including surgical resection and percutaneous local ablation,
are only effective in early stage HCC, and orthotopic liver transplantation is only possible in a
limited number of patients [7]. Systemic therapy with multikinase inhibitors, including sorafenib and
lenvatinib, only yield minor survival benefits, which are offset by considerable adverse events [4,8].
Even though immune checkpoint inhibitors are promising new drugs in the therapeutic landscape of
HCC and have shown a survival benefit when combined with the antivascular endothelial growth factor
(VEGF) antibody bevacizumab, there is still an unmet need for more effective treatment strategies, since
immunotherapy is not effective or applicable in all HCC patients [9,10]. In addition, the coexistence
with chronic liver disease severely hampers the utilization of several biomarkers for the surveillance
and early diagnosis of HCC, with alpha-fetoprotein (AFP) to date being the only widely used serum
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biomarker in daily practice [11]. Thus, it is of the utmost importance to continue refining and
broadening the current understanding of the complex pathogenesis of HCC to enable the discovery of
new therapeutic targets and biomarkers for early HCC diagnosis.
2. Angiogenic Sprouting in HCC
Angiogenesis plays a major role in the growth, progression and metastasis of HCC, a
characteristically hypervascular tumor [12,13]. Indeed, in order to meet the increased oxygen
and nutrient consumption of this fast-growing tumor, the formation of new blood vessels is
essential [12,14]. In neovascularization, endothelial cells of pre-existing vessels proliferate and
migrate to form vascular sprouts [15]. During HCC growth and dedifferentiation, a switch from
portal venous to predominantly arterial blood supply occurs, and well-developed artery-like vessels
characterize angiogenic sprouting [12,16]. This complex multi-step process is induced by a balanced
shift between multiple pro- and antiangiogenic factors, known as the angiogenic switch, with VEGF and
angiopoietins (Angs) as key contributors to HCC angiogenesis [15–18]. Both of these angiogenic growth
factor families serve as ligands of receptor tyrosine kinases, which are almost exclusively expressed
on the surface of endothelial cells, and they have complementary and coordinated functions in
neovascularization [16,19,20]. VEGF mediates angiogenesis by inducting endothelial cell proliferation,
migration and tube formation, as well as by increasing the vascular permeability [16,21]. The expression
of VEGF and its receptors is upregulated in various human cancers, including HCC, and often
correlates with microvessel density (MVD), invasiveness and poor prognosis [21,22]. Consequently,
anti-VEGF strategies have been extensively explored and represent an important component of
today’s systemic anticancer therapy [23]. In this regard, a combination therapy of the VEGF-targeting
monoclonal antibody bevacizumab with the immune checkpoint inhibitor (ICI) atezolizumab has
shown very promising effects on the survival of unresectable HCC patients in a phase 3 trial [10].
This synergistic antitumor effect of combined VEGF target and ICI therapy may be explained by the
vasculature normalization established by the antiangiogenic agent, which improves the efficacy of
the immunotherapeutic compound [10,24,25]. The other key factor in HCC angiogenesis, Ang-2, also
exerts immunosuppressive activities via involvement in the recruitment of monocytes/macrophages
in the tumor microenvironment (TME) and induction of the expression of the immune checkpoint
programmed death-ligand 1 (PD-L1) on the surface of tumor-associated macrophages (TAMs) and
may thus also contribute to the resistance to ICI therapy. As Ang-2 mediates resistance to anti-VEGF
therapy as well, and Ang-2 targeting may promote restoration of the hepatic vasculature, the addition
of an Ang-2-targeting compound to the combination of anti-VEGF and ICI therapy could potentially
further improve its efficacy in HCC patients [26]. The Ang/tyrosine kinase with immunoglobulin (Ig)
and epidermal growth factor (EGF) homology domains 2 (Tie2) system thus exerts a critical role in
neovascularization in conjunction with VEGF and might also present an interesting therapeutic target
for HCC, as discussed further (Figure 1) [16,27].
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Figure 1. Angiopoietin-2-mediated vascular sprouting in hepatocellular carcinoma. Vascular 
remodeling is crucial for the growth and progression of hepatocellular carcinoma (HCC) [12,13]. The 
formation of new blood vessels is induced by the angiogenic switch, which implies an intratumoral 
balance shift in favor of proangiogenic factors, including vascular endothelial growth factor (VEGF) 
and angiopoietin (Ang)-2 [15–18]. Overexpression of Ang-2 may be mediated by hypoxia [28], VEGF 
overexpression [29], cyclooxygenase (COX)-2 overexpression [30] and AT-rich interactive domain-
containing protein 1A (Arid1a) deficiency [31], among others, and alters the quantitative balance 
between Ang-1 and Ang-2 expression in favor of Ang-2 [21]. Subsequent interaction with its receptor, 
tyrosine kinase with immunoglobulin (Ig) and epidermal growth factor (EGF) homology domains 2 
(Tie2), which are predominantly expressed on the surface of endothelial cells, result in vessel 
destabilization and, thereby, facilitates other proangiogenic factors, including VEGF, to induce 
vascular sprouting [32,33]. Ang-2 is thus dependent on VEGF/VEGF receptor (VEGFR) signaling to 
exert its effect on HCC angiogenesis and progression [27]. Despite the complexity of Ang-2-mediated 
HCC neovascularization, Ang-2 could potentially serve as a circulating or tissue biomarker for HCC, 
and therapeutic opportunities lie in direct or indirect targeting of this Ang-2/Tie2 signaling pathway. 
This figure was created with BioRender.com. 
3. Role of Angiopoietins in Angiogenic Sprouting 
Over two decades ago, Yancopoulous et al. discovered a novel family of growth factors 
specifically binding to an endothelial cell-expressed receptor tyrosine kinase, consisting of four 
members: Angs 1–4 [29,34–36]. Despite all of these being ligands of the Tie2 receptor, a ligand-
receptor interaction leads to different subtype-specific biological actions [37]. The exact functions of 
the murine Ang-3 and its human ortholog Ang-4 are poorly characterized, while Ang-1 and Ang-2 
are considered the two pivotal angiogenesis-mediating members of the Ang family [15,37]. Ang-1 is 
widely expressed in tissues during adult life, activates the Tie2 receptor via phosphorylation and 
mediates the stabilization and maturation of developing vessels by strengthening endothelial cell-
cell junctions and by promoting the recruitment of pericytes and smooth muscle cells [20,22]. In 
contrast, Ang-2 is primarily expressed in endothelial cells, where it is stored in specialized Weibel-
Palade bodies from which it can be rapidly released upon cytokine stimulation. Ang-2 has a similar 
Tie2 receptor affinity as Ang-1 and is a context-dependent Tie2 agonist/antagonist that activates the 
Tie2 receptor under homeostatic conditions and inhibits Tie2 phosphorylation in the presence of 
inflammation [15,38]. However, both Ang-2-mediated overactivation and inactivation of Tie2 can 
contribute to vascular remodeling [39]. Under physiologic conditions, Ang-2 expression is markedly 
increased only at sites of active vascular remodeling, such as the female reproductive tract [16,20]. 
On the other hand, Ang-2 is overexpressed in a wide range of inflammatory conditions, including 
HCC, which is a typical inflammation-associated cancer [40,41]. Ang-2/Tie2 signaling results in vessel 
destabilization, which facilitates proangiogenic factors, including VEGF, to induce 
Figure 1. Angiopoietin-2-mediated vascular sprouting in hepatocellular carcinoma. Vascular
remodeling is crucial for the growth and progression of hepatocellular carcinoma (HCC) [12,13].
The formation of new blood vessels is induced by the angiogenic switch, which implies an intratumoral
balance shift in favor of proangiogenic factors, including vascular endothelial growth factor (VEGF)
and angiopoietin (An )-2 [15–18]. Overexpression of Ang-2 may be mediated by hypoxia [28],
VEGF overexpression [29], cyclooxygenase (COX)-2 overexpression [30] and AT-rich interactive
domain-containing protein 1A (Arid1a) deficiency [31], among others, and alters the quantitative
balance between Ang-1 and Ang-2 expression in favor of Ang-2 [21]. Subsequent interaction with its
receptor, tyrosine kinase with immunoglobulin (Ig) and epidermal growth factor (EGF) homology
domains 2 (Tie2), which are predominantly expressed on the surface of endothelial cells, result in vessel
destabil zation and, thereby, facilit tes other p oangiogenic factors, including VEGF, t induce vascular
sprouting [32,33]. Ang-2 is thus dependent on VEGF/VEGF receptor (VEGFR) signaling to exert its
effect on HCC angiogenesis and progression [27]. Despite the complexity of Ang-2-mediated HCC
neovascularization, Ang-2 could potentially serve as a circulating or tissue biomarker for HCC, and
therapeutic opportunities lie in direct or indirect targeting of this Ang-2/Tie2 signaling pathway. This
figure was created with BioRender.com.
3. Role of Angiopoietins in Angiogenic Sprouting
Over two decades ago, Yancopoulous et al. discovered a novel family of growth factors specifically
binding to an endothelial cell-expressed receptor tyrosine kinase, consisting of four members: Angs
1–4 [29,34–36]. Despite all of these being ligands of the Tie2 receptor, a ligand-receptor interaction leads
to different subtype-specific biological actions [37]. The exact functions of the murine Ang-3 and its
human ortholo Ang-4 are po rly characterized, while Ang-1 nd Ang-2 are considered the two pivotal
angiogenesis-mediating members of the Ang family [15,37]. Ang-1 is widely expressed in tissues during
adult life, activates the Tie2 receptor via phosphorylation and mediates the stabilization and maturation
of developing vessels by strengthening endothelial cell-cell junctions and by promoting the recruitment
of pericytes and smooth muscle cells [20,22]. In contrast, Ang-2 is primarily expressed in endothelial
cells, where it is stored in specialized Weibel-Palade bodies from which it can be rapidly released upon
cytokine stimula ion. Ang-2 has a i ilar Tie2 receptor affinity as Ang-1 and is a context-dependent
Tie2 agonist/antagonist that activates the Tie2 receptor under homeostatic conditions and inhibits
Tie2 phosphorylation in the presence of inflammation [15,38]. However, both Ang-2-mediated
overactivation and inactivation of Tie2 can contribute to vascular remodeling [39]. Under physiologic
conditions, Ang-2 expression is markedly increased only at sites of active vascular remodeling, such as
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the female reproductive tract [16,20]. On the other hand, Ang-2 is overexpressed in a wide range of
inflammatory conditions, including HCC, which is a typical inflammation-associated cancer [40,41].
Ang-2/Tie2 signaling results in vessel destabilization, which facilitates proangiogenic factors, including
VEGF, to induce neovascularization [32,33]. Indeed, in the presence of VEGF, Ang-2 mediates vascular
sprouting and angiogenesis [22]. However, as Angs themselves do not promote endothelial cell
proliferation, Ang-2/Tie2 signaling results in vessel regression in the absence of VEGF [15,16,27,33].
In a variety of human malignancies, including HCC, Ang-2 overexpression is correlated with MVD,
several clinicopathological parameters and poor prognosis, as further discussed [15,22,32].
4. Angiopoietin Expression and Signaling in HCC
4.1. Angiopoietin-2 Expression in HCC
In 1999, Tanaka et al. were the first to show a close association between Ang-2 expression
and hypervascularity in human HCC. In addition, they demonstrated that Ang-2 overexpression
promotes rapid tumor development and worsens prognosis in an ectopic xenograft model of human
HCC [32]. Correlation of the overexpression of both Ang-2 and Tie2 with angiogenesis, as well as
certain histopathological parameters in human HCC, confirmed that Ang-2/Tie2 angiogenic signaling
may be implicated in the biological behavior of HCC [42]. Moreover, inhibition of the Tie2 receptor
suppressed tumor neovascularization and growth in an HCC mouse model, leading to the suggestion
that, in addition to serving as a Tie2 antagonist, Ang-2 may possibly also activate Tie2 as an agonist,
resulting in stimulation of a fundamentally different signaling pathway compared to Ang-1 [19].
Later on, Yoshiji et al. demonstrated the VEGF dependency of Ang-2 to exert its effect on HCC
angiogenesis and development. Whereas a combined overexpression of Ang-2 and VEGF in HCC
resulted in markedly increased tumor development and neovascularization, significant upregulation
of matrix metalloproteinase (MMP)-2 and MMP-9 expression and a marked reduction of intratumoral
apoptosis and vessel maturation; these effects were not observed or far less pronounced following the
overexpression of, respectively, Ang-2 and VEGF alone. Moreover, the inhibition of VEGF signaling
abrogated the effect of combined Ang-2 and VEGF overexpression on HCC tumor development. These
findings lead to the suggestion that the synergistic effect of Ang-2 and VEGF on HCC angiogenesis
and development is partly mediated by reduced intratumoral apoptosis and the failure of tumor vessel
maturation, as well as an induction of MMP-2 and MMP-9 [27].
Several studies have further investigated the underlying regulatory pathways of Ang-2. As
hypoxia is considered as an important stimulus of angiogenic signaling in cancer and is involved in
the upregulation of VEGF in HCC; Ang-2/Tie2 signaling might also be hypoxia-driven in HCC [17].
Several groups did not observe differences in either Ang-1 or Ang-2 mRNA expression in human HCC
cell lines under hypoxic conditions and suggested that hypoxia does not regulate Ang expression in
HCC [17,33]. However, Ang-2 release from Weibel-Palade bodies is increased in hypoxia-stimulated
endothelial cells, and this might contribute to Ang-2 overexpression in the hypoxic microenvironment
of HCC tissue [28]. Furthermore, VEGF has been shown to upregulate the expression of Ang-1 and
Ang-2; thus, hypoxia-induced VEGF overexpression may also be involved in Ang-2 overexpression in
HCC [29].
Tanaka et al. suggested a regulatory role of cyclooxygenase (COX)-2 in the expression of Ang-2
in HCC, since specific COX-2 inhibition attenuated Ang-2 expression, as well as inhibited tumor
angiogenesis and growth in a subcutaneous syngeneic HCC mouse model. Therefore, although further
exploration of the underlying regulatory mechanisms is needed, modulation of Ang-2 regulators,
including COX-2, might be a potential therapeutic strategy in HCC [30].
Recent advances in cancer exome sequencing have led to the identification of AT-rich interactive
domain-containing protein 1A (Arid1a), a key member of the switch/sucrose nonfermentable (SWI/SNF)
chromatin-remodeling complex, as one of the genes that is most frequently mutated in human HCC,
present in approximately 10–15% of the patients [31,43]. Arid1a deficiency resulted in the upregulation
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of Ang-2 in HCC tissue through histone H3K27ac modification at the Ang-2 gene locus. Importantly,
sorafenib is able to counteract this protumorigenic effect in Arid1a-deficient HCC by reducing H3K27ac
deposition at the Ang-2 gene locus and, consequently, epigenetically downregulating Ang-2 expression.
As Arid1a deficiency seems to result in higher susceptibility to sorafenib treatment, screening for this
mutation may enable the specific selection of HCC patients who are more likely to benefit from this
systemic therapy [31].
4.2. Angiopoietin-1 Expression in HCC
Several groups demonstrated similar Ang-1 expression in HCC and adjacent nonmalignant
hepatic tissue [21,32]. As Ang-1 and Ang-2 compete for interaction with the same receptor, and Ang-2
expression is upregulated in human HCC tissue, Mitsuhashi et al. suggested that the quantitative
balance between Ang-1 and Ang-2 expression might be a better way to assess the role of Ang signaling on
HCC angiogenesis and progression. They demonstrated that, in the presence of VEGF, the Ang-2/Ang-1
mRNA ratio was indeed closely associated with angiogenesis, several clinicopathological parameters
and a poor prognosis in HCC [21]. Several groups did observe an overexpression of Ang-1 in human
HCC samples. However, in contrast to Ang-2 expression, Ang-1 upregulation did not correlate with
angiogenesis or tumor progression, strengthening the proposal of Mitsuhashi et al. to consider the
Ang-2/Ang-1 ratio instead of focusing on individual expressions of the two Ang subtypes [20,33].
Sugimachi et al. demonstrated that the progression from normal hepatic tissue to HCC is accompanied
by an induced expression of Ang-2 and suppression of Ang-1 expression. However, progression to a
less-differentiated tumor seems to be associated with an upregulation of both Ang subtypes. Therefore,
as the Ang-2 expression is higher at the invasive front of the HCC tissue, compared to the center of the
tumor, and Ang-2 overexpression contributes to VEGF-mediated neovascularization of the growing
tumor; the upregulation of Ang-1 might promote stabilization and maturation of the newly-formed
vessels [17].
Lin et al. also observed Ang-1 overexpression in HCC tissue. As previous studies had reported
that HCC progression is promoted by activated hepatic stellate cell (HSC)-mediated microvessel
formation, and the expression of Ang-1 was positively correlated with the MVD and α-smooth muscle
actin (α-SMA) expression, the authors suggested that activated HSCs mediate angiogenesis through the
upregulation of Ang-1 expression and, thereby, promote HCC growth and metastasis [44]. An obvious
shortcoming of this study is the fact that the authors did not determine the intratumoral Ang-2
expression and, thus, had no insight into the quantitative balance between both Ang subtypes, and the
resultant nature and magnitude of the Ang/Tie2 signal.
5. Role of Angiopoetin-2 in Nonsprouting Vascular Remodeling in HCC
In stark contrast to multiple studies cited above, Zeng et al. did not detect convincing changes
in either Ang-1 or Ang-2 expression in HCC tissue and observed an Ang-2/Ang-1 mRNA ratio that
was multiple times lower compared to renal cell carcinoma (RCC), one of the most highly angiogenic
human cancers. Therefore, they proposed that Ang/Tie2-mediated angiogenesis may not play a major
role in HCC tumorigenesis. Moreover, in their study, VEGF expression was not upregulated as well,
strengthening their hypothesis that HCC-mediated vascular remodeling may rely on other mechanisms
than angiogenic sprouting [45]. Two such additional mechanisms for tumor blood supply that have
been described in HCC are sinusoidal capillarization and vessel co-option. Sinusoidal capillarization,
which has been found to be a common neoangiogenic process in HCC, implies a transformation
of the discontinuous hepatic sinusoids into continuous capillaries. Well-differentiated HCC tissue
contains microvessels of both the sinusoidal and capillary type, whereas only the capillary type is
present in poorly differentiated HCC, so sinusoidal capillarization appears to be associated with
tumor dedifferentiation [12]. Ang-1 may be involved in the stabilization and maturation of these
vessels, by promoting pericyte recruitment [45]. In vessel co-option, tumor cells grow along the
pre-existing vasculature without eliciting an angiogenic response. However, as the tumor grows, the
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co-opted vessels will upregulate Ang-2 expression, which, due to the lack of VEGF expression, first
leads to vascular regression. The subsequent formation of a hypoxic core stimulates coincident VEGF
upregulation and induces angiogenesis [46,47]. Thus, alternative mechanisms for vascular remodeling
may also be implicated in HCC tumorigenesis. The involvement of each of these mechanisms may
shift during HCC development and progression, depending on the balance of proangiogenic and
antiangiogenic factors.
Fang et al. described the existence of a vascular pattern of sinusoid-like vessels that closely
surrounds individual tumor clusters in HCC, named vessels that encapsulate the tumor cluster (VETC).
They found that the development of this vascular pattern depends on the presence of intratumoral Ang-2,
as VETC-positive HCC tissue displays a higher Ang-2 expression and the intratumoral inhibition of
Ang-2 disrupts the formation of this VETC pattern in vivo. Moreover, Ang-2 inhibition also suppresses
the in vivo metastasis of HCC, suggesting that this Ang-2-dependent VETC pattern is involved in HCC
metastasis [48]. Subsequently, Zhou et al. identified two microRNAs (miRNAs) that act as suppressors
of VETC formation and VETC-dependent metastasis, through the inhibition of Ang-2 expression,
either directly in case of miR-125b or, indirectly, through suppression of the mammalian target of the
rapamycin (mTOR)-p70S6K signaling pathway in case of miR-100. HCC patients with low levels of
these miRNAs have a high intratumoral Ang-2 expression and may therefore be more susceptible to
tumor metastasis. Consequently, Ang-2 targeting may disrupt the formation of VETC, and miR-125b
and miR-100 may represent new promising targets for the prevention of HCC metastasis [49].
6. Angiopoietin-Targeting Therapeutic Strategies in HCC
6.1. Angiopoietin Targeting in Context of Chemotherapy
Several chemotherapeutic strategies have been shown to influence Ang-2/Tie2 signaling in HCC.
Wada et al. demonstrated the therapeutic potential of combined interferon gamma (IFN-γ) and
fluorouracil (5-FU) treatments by inhibiting tumor cell proliferation and angiogenesis and inducing
intratumoral apoptosis. These effects were accompanied by a significant decrease in Ang-2 expression
and increase in Ang-1 expression in an HCC mouse model [50]. The authors suggested that the
enhanced antitumorigenic effect of 5-FU may be partially explained by an improvement of its delivery
to the HCC tumor, as IFN-γ-mediated Ang regulation may cause intratumoral vessel stabilization
and the reduction of vascular permeability [51]. Similarly, a significant downregulation of Ang-2
expression was also observed following interstitial chemotherapy using poly(lactic-co-glycolic acid)
(PLGA) microspheres containing docetaxel in an HCC mouse model, suggesting that inhibition
of Ang-2/Tie2-mediated angiogenesis may be an important mechanism involved in its antitumor
activity [52].
Li et al. were the first to demonstrate that Ang-2 is able to enhance chemoresistance in HCC.
In a human HCC cell line, they showed that Ang-2/Tie2 signaling attenuates doxorubicin-induced
apoptosis. This antiapoptotic effect is mainly achieved through prevention of doxorubicin-induced
oxidative stress and mitochondrial dysfunction. The underlying mechanism of this Ang-2-mediated
chemoresistance is upregulation of the expression of survivin and Ref-1 through the Tie2-extracellular
signal-regulated kinase (ERK)-mitogen- and stress-activated protein kinase (MSK) cascade. Ang-2
targeting thus not only represents a promising antiangiogenic therapeutic strategy but may, in addition,
also be of interest to increase chemosensitivity in HCC patients [53]. The additional finding that a
Tie2-neutralizing antibody led to reversal of the Ang-2-mediated chemoresistance suggests that, in
addition to serving as a biological antagonist of Ang-1, Ang-2 can also act as a context-dependent Tie2
agonist, which is something that was already previously put forward by Tanaka et al. [19,53].
6.2. Direct Angiopoietin-Targeting Therapeutic Strategies
Agents that directly target Ang-2 expression are emerging. In 2014, Zhang et al. were the first to
demonstrate the effect of direct Ang-2 targeting on HCC angiogenesis and progression in vivo. For
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this, they purified a single-chain variable fragment against human Ang-2 (scFv-Ang2) that significantly
reduced endothelial migration and tubule formation in vitro and investigated its antitumor potential
in a highly metastatic murine orthotopic xenograft model of human HCC. scFv-Ang2 treatment led to
significant inhibition of HCC angiogenesis and growth, as well as partial inhibition of intrahepatic
metastasis and metastatic spread to the lungs [54]. These beneficial effects on in vivo HCC angiogenesis
and progression suggest that the direct targeting of Ang-2 could be an effective therapeutic strategy
in HCC patients. T7 peptide, a fragment of the endogenic antiangiogenic factor tumstatin, has also
been investigated as an antimetastatic inhibitor of Ang-2 in the context of HCC. The administration
of T7 peptide downregulated the hypoxia-induced expression of Ang-2 in endothelial cells through
the inhibition of Akt (protein kinase B) phosphorylation. This resulted in the inhibition of both
angiogenesis and HCC tumor cell invasion. However, as these promising antitumor properties of
T7 peptide were only demonstrated in vitro, they must be validated in a subsequent in vivo study in
order to prove its therapeutic potential in HCC [28]. Recently, a study from our group showed that
Ang-2 inhibition prevents the progression of chronic liver disease towards HCC. In addition to its
beneficial effect on steatohepatitis and fibrosis, the treatment with the Ang-2/Tie2 interaction-inhibiting
peptibody L1-10 in a mouse model of diabetes-associated NAFLD attenuated HCC development [38].
In order to further explore the role of Ang-2 in the progression of chronic liver disease, it would be
interesting to investigate the effects of Ang-2 inhibition on HCC development in experimental models
of ALD and chronic liver disease due to hepatitis B virus (HBV) or hepatitis C virus (HCV) infections.
Table 1 summarizes the experimental HCC animal models used in Ang-related research to date. Most
of these HCC models are implantation models in which murine or human HCC cells are orthotopically
or subcutaneously injected in mice.
The human anti-Ang-2 monoclonal antibody nesvacumab was the first direct Ang-2-targeting
therapy in a first-in-human phase I study (NCT01271972) in patients with advanced solid tumors. In
this clinical trial, two HCC patients showed stable disease, with tumor regression and significant AFP
decline [55].
Table 1. Hepatocellular carcinoma (HCC) animal models used in angiopoietin-related research to date.
Experimental HCC Animal Model Ref.
Diethylnitrosamine-induced HCC rat model [56]
Diethylnitrosamine-induced HCC mouse model [31]
Nonalcoholic steatohepatitis-induced HCC mouse model [38]
Subcutaneous syngeneic HCC mouse model
(injection of MH134 cells in C3H mice) [30]
Subcutaneous syngeneic HCC mouse model
(injection of Hepa1-6 cells in C57BL/6 mice) [48,49]
Orthotopic syngeneic HCC mouse model
(injection of Hepa1-6 cells in C57BL/6 J mice) [48,49]
Murine subcutaneous xenograft model of human HCC
(injection of BEL-7404 cells in BALB/c nude mice) [52]
Murine orthotopic xenograft model of human HCC
(injection of VETC-2 cells in BALB/c nude mice) [49]
Highly metastatic murine orthotopic xenograft model of human HCC
(implantation of metastatic tumor tissue of murine subcutaneous
xenograft model of human HCC in BALB/c nude mice)
[54]
7. Angiopoietins as Diagnostic and Prognostic Biomarkers
Scholz et al. were the first to show that, in addition to an upregulation in HCC tissue, Ang-2 levels
are also elevated in the blood of HCC patients, leading to its potential as a serum biomarker for HCC.
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However, no correlation between Ang-2 serum levels and tumor characteristics could be demonstrated.
As they already observed elevated Ang-2 serum levels in cirrhotic patients, the authors speculated
that locally and systemically increased Ang-2 levels may contribute to the development of HCC in
patients suffering from cirrhotic liver disease [57]. Kuboki et al. showed a significant correlation
between hepatic (but not peripheral) venous Ang-2 levels and Ang-2 mRNA expression and the MVD
in HCC tissues, suggesting that hepatic venous Ang-2 levels reflect HCC neovascularization more
precisely compared to peripheral venous levels. However, also for hepatic venous Ang-2 levels, no
correlation with clinicopathological parameters of HCC was found, except for portal vein invasion [58].
In contrast, other groups observed strong correlations between systemic Ang-2 levels and tumor
stage and the Child-Pugh score [13,59]. Llovet et al. reported on Ang-2 plasma levels as a strong,
independent prognosis predictor in patients with HCC, since high Ang-2 plasma levels correlated with
poor survival, shorter time to progression and several other clinical/demographic variables associated
with a poor outcome in advanced HCC [60].
In 2016, a five-gene transcriptomic hepatic signature, which includes Ang-2 as the most significantly
upregulated gene, in addition to delta-like ligand 4 (DLL4), neuropilin/tolloid-like 2 (NETO2),
endothelial cell-specific molecule-1 (ESM1) and nuclear receptor subfamily 4 group A member 1
(NR4A1), was identified to predict HCC growth and prognosis in individual patients. Adding the
prognostic information of this five-gene signature to the parameters that are already used in daily
practice could lead to a more personalized therapeutic management of HCC patients by allowing
better stratification of these patients into clinically relevant subgroups [61].
Teixeira et al. recently demonstrated the differential expression of Ang-2 in HCC lesions compared
to non-neoplastic regenerative nodules. They suggested that, in addition to its clear potential as a
predictive or prognostic biomarker, Ang-2 might also serve as a diagnostic biomarker in the pathologic
interpretation of malignancy in hepatocellular nodules. Anti-Ang-2 immunohistochemistry (IHC)
might, for instance, be added to the current triple-IHC panel for HCC diagnosis, consisting of heat
shock protein 70 (Hsp70), glypican-3 and glutamine-synthetase, and thereby contribute to the handling
of challenging cases [62].
7.1. Angiopoietins as Biomarker in Nonsystemic HCC Treatment
If HCC is diagnosed at an early stage in patients with a reasonable liver function, the preferred
treatment is surgical resection [7]. Whereas several groups showed that Ang-2 expression in patient
HCC tissues is predictive for recurrence after surgical resection [22,63], Kuboki et al. were the first to
demonstrate that high preoperative hepatic venous Ang-2 levels correlate with a shorter postoperative
survival, strengthening the prognostic value of Ang-2 [58]. Diaz-Sanchez et al. confirmed this
correlation between high hepatic venous Ang-2 levels and the unfeasibility of both surgical and
locoregional curative treatments [13]. A high preoperative Ang-2 level in the hepatic vein may thus
reflect a more advanced stage of HCC, in which surgical resection and other curative treatments
are ineffective [7,22,58]. Following resection, Ang-2 levels in both the hepatic and peripheral vein
decreased significantly [58].
Orthotopic liver transplantation represents the best curative option for early stage HCC patients
with underlying cirrhosis [7]. Atanasov et al. assessed the influence of Ang expression and the presence
of Tie2-expressing monocytes (TEMs) in the explanted liver prior to liver transplantation on graft
rejection and patient survival. Pretransplant Ang-2 expression was associated with graft rejection
after transplantation. Moreover, the presence of TEMs was associated with lower post-transplant
survival [64]. Therefore, Ang-2 and TEMs could serve as predictive serum biomarkers for the
stratification of patients who are more likely to benefit from liver transplantation [65,66].
Once HCC has progressed to an intermediate stage, transcatheter arterial chemoembolization
(TACE) represents the therapeutic gold standard for patients without concurrent portal vein
thrombosis [67]. This locoregional therapy is based on specific occlusion of the arterial blood
supply of the tumor, which progressively develops during HCC dedifferentiation, combined with
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injection of chemotherapeutic drugs [7,67]. Contradictory findings have been reported on the effect of
TACE on circulating Ang-2 levels. Hsieh et al. observed a significant TACE-induced increase in Ang-2
serum levels, whereas Diaz-Sanchez et al. did not notice statistically different levels of circulating
Ang-2 after locoregional HCC treatment with radiofrequency ablation (RFA) or TACE [13,59].
As an alternative for TACE, transarterial radioembolization (TARE) can be considered for
intermediate-stage HCC [7]. In this locoregional therapy, small radioisotope-containing microspheres
are delivered directly into the tumor through its arterial blood supply [7,68]. A major advantage over
TACE is the fact that portal vein thrombosis is not a contraindication for TARE [7]. Carpizo et al. detected
higher baseline Ang-2 serum levels in liver cancer patients with shorter survival after yttrium-90 (90Y)
radioembolization therapy, making it a potentially useful biomarker for post-treatment prognosis.
Increased Ang-2 expression might thus indicate a worse survival of HCC patients undergoing TARE
by either promoting neovascularization or by negatively influencing the effectiveness of TARE [68].
7.2. Angiopoietins as a Biomarker in Sorafenib Treatment
The oral multikinase inhibitor sorafenib was the first systemic therapeutic option to gain approval
for use in HCC patients [4]. Despite the minor survival benefit, and considerable adverse events
to date, it is still considered as the first-line treatment for unresectable advanced HCC, together
with lenvatinib [4,8,69]. Sorafenib exerts its antitumor effect through the inhibition of several targets
involved in HCC angiogenesis and progression, including vascular endothelial growth factor receptors
(VEGFRs) 1-3, platelet-derived growth factor receptor beta (PDGFR-β), mast/stem cell growth factor
receptor (c-KIT) and rearranged during transfection (RET), as well as several rapidly accelerated
fibrosarcoma (Raf) kinases [4,7,69]. As a portion of HCC patients does not show a response to this
antiangiogenic treatment, the identification of angiogenesis-related serum biomarkers to predict which
patients are likely to benefit from this therapy is an area of active interest [69,70]. Miyahara et al. were
the first to demonstrate a negative correlation between circulating Ang-2 levels and drug response and
post-treatment progression-free survival in sorafenib-treated HCC patients. Measurement of baseline
Ang-2 serum levels predicted the efficacy of sorafenib treatment in advanced HCC patients [70].
In a large biomarker study, Llovet et al. showed that sorafenib treatment is able to halt the disease
progression-associated increase in circulating Ang-2 in patients with advanced HCC. As increases in
circulating Ang-2 during sorafenib treatment were associated with a poor outcome, measuring the serum
level of this angiogenic factor may be of interest in disease monitoring during treatment [60]. In addition
to the potential of circulating Ang-2 as a prognostic biomarker in sorafenib treatment of advanced HCC
patients, recently, three ANGPT2 (Ang-2 gene) rs55633437 single-nucleotide polymorphisms (SNPs)
have been identified that correlate with patient survival and response to sorafenib. These ANGPT2
polymorphisms may thus potentially serve as genetic biomarkers for HCC patient stratification [71].
7.3. Angiopoietins as Biomarkers in Other Systemic Treatments
As high-circulating Ang-2 levels are associated with poor prognosis, addition of the Ang-1 and
Ang-2-neutralizing peptibody trebananib to the sorafenib treatment could improve the survival of
advanced HCC patients. However, this combination of antiangiogenic agents did not demonstrate
improved disease control. A possible explanation for this lack of additional disease improvement
is the potential existence of a nonexceedable maximum benefit from antiangiogenic therapy. If
this is the case, in order to achieve further progress in advanced HCC treatment, antiangiogenic
agents should be combined with therapeutic strategies that target other cancer hallmarks, such as
immunotherapeutic approaches [72]. In this regard, a combination therapy of the immune checkpoint
inhibitor atezolizumab and the VEGF-targeting monoclonal antibody bevacizumab in patients with
unresectable HCC resulted in superior survival outcomes compared to sorafenib in a phase 3 trial and
will, therefore, become the new standard of care in this setting [10,73]. In the case of failure of sorafenib
treatment, regorafenib is a second-line systemic treatment option [4]. Interestingly, in addition to
sharing common targets with sorafenib, such as VEGFRs 1-3, PDGFR-β and RET, regorafenib also
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inhibits Tie2. Recently, Teufel et al. identified low baseline circulating Ang-1 levels as predictive for
higher overall survival after regorafenib treatment [74].
In addition to these multikinase inhibitors that are already approved for first- or second-line
treatment of advanced HCC, several other antiangiogenic therapies have been or are being tested in
clinical trials [75]. Concerning the utilization of circulating Ang-2 levels as a predictive or prognostic
biomarker in advanced HCC, Kaseb et al. reported that elevated Ang-2 plasma levels were associated
with poor prognosis in advanced HCC patients treated with a combination of the bevacizumab and
the oral tyrosine kinase inhibitor erlotinib [76]. Kang et al. also observed a correlation between high
baseline circulating Ang-2 levels and poor prognosis after the second-line treatment of advanced HCC
patients with the tyrosine kinase inhibitor axitinib [77].
In Table 2, we provide an overview of existing indications for Angs to serve as a biomarker in
HCC diagnosis or treatment.
Table 2. Biomarker potential of tissue and circulating angiopoietins in HCC diagnosis and treatment.
Ang: angiopoietin.
Diagnosis/Treatment Biomarker Potential Ref.
Diagnosis Ang-2 expression is higher in HCC tissue compared to
adjacent noncancerous liver tissue.
[15,20,21,32,33,42,63]
Circulating Ang-2 levels are higher in HCC patients
compared to cirrhosis patients.
[57,78]
Ang-2 expression is higher in HCC tissue compared to
benign liver disease tissue.
[79]
Differential Ang-2 expression in HCC lesions, compared to
non-neoplastic regenerative nodules.
[62]
Surgical resection Ang-2 expression in HCC tissue correlates with
post-surgery recurrence.
[22,63]
Preoperative hepatic venous Ang-2 levels inversely correlate
with post-surgery survival.
[58]










Circulating Ang-2 levels inversely correlate with eligibility
for surgical or locoregional treatment.
[13]
Sorafenib Baseline circulating Ang-2 levels inversely correlate with
response to sorafenib.
[70]
Baseline circulating Ang-2 levels inversely correlate with
post-treatment time to progression and overall survival.
[60,70,80,81]
Post-treatment increases of circulating Ang-2 levels inversely
correlate with time to progression and overall survival.
[60]
Regorafenib Baseline circulating Ang-1 levels inversely correlate with
post-treatment overall survival.
[74]
8. Alternative Angiopoietin-2-Related Targets and Biomarkers in HCC
Tie2-expressing monocytes (TEMs) are a proangiogenic subpopulation of peripheral and
tumor-infiltrating myeloid cells, which have been reported in several angiogenesis-mediated cancers,
including renal, colorectal, pancreatic and lung carcinoma, as well as HCC. The number of TEMs,
characterized as CD14+CD16+Tie2+ monocytes, is significantly increased in blood and tumoral
tissues of HCC patients and is positively correlated with Ang-2 expression and angiogenesis in HCC
tissues. In the liver, TEMs preferentially accumulate in the perivascular areas of HCC tissues. These
findings suggest that TEMs may contribute to HCC-mediated angiogenesis [65,82]. As Matsubara et al.
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demonstrated, a positive correlation between the frequency of TEMs in the blood and the severity of
liver disease and post-therapy recurrence rate, TEM frequency could represent a prognostic biomarker
in HCC patients [65]. He et al. also suggested that circulating TEMs may predict the prognosis of
patients with HCC, as they observed a negative correlation between TEM percentages in the blood
and post-resection survival [82]. TEM frequency also changes dynamically in relation to curative
surgical or locoregional treatment and post-treatment recurrence, adding to its prognostic value [65].
Furthermore, the predictive power of circulating TEMs was confirmed in liver transplantation and
sorafenib-treated HCC patients as well, as, in both cases, TEMs are associated with survival [64,83]. In
addition, the frequency of circulating TEMs was found to be superior to levels of the HCC-specific
serum marker AFP in differentiating HCC from chronic liver disease or cirrhosis and may, thus, also
represent a complementary diagnostic biomarker for HCC [65].
Very recently, Xie et al. described the existence of Ang-2-expressing HCC-derived exosomes.
These exosomes are internalized and recycled in endothelial cells, and thus, exosomal Ang-2 interacts
differently with its recipient cells compared to soluble Ang-2. HCC cell-secreted exosomal Ang-2
seems to promote HCC angiogenesis and progression independent of the Ang-2/Tie2-signaling
pathway by activation of the Akt/endothelial nitric oxide synthase (eNOS) and Akt/β-catenin pathways.
Consequently, the existence of these alternative signaling pathways for exosomal Ang-2 reveals novel
potential targets for the treatment of HCC [79].
9. Conclusions
The role of Ang-2/Tie2 signaling in HCC angiogenesis and progression is complex. In addition to
its proportional expression compared to Ang-1, Ang-2 is dependent on the presence of VEGF, and the
overall balance between proangiogenic and antiangiogenic factors, to contribute to HCC angiogenesis.
Ang-2 expression is regulated by multiple mechanisms, and Angs exert several functions through
alternative Ang/Tie2-independent signaling pathways. Multiple therapeutic approaches have been
demonstrated to target Ang-2, either directly or indirectly, in HCC. However, to date, none of these
approaches has resulted in a truly satisfying antiangiogenic treatment for advanced HCC, again
illustrating the complexity of its angiogenic landscape. The potential of Ang-2 as a prognosis predictor
is shown for a broad range of therapeutic strategies and HCC stages, ranging from surgical approaches
in early HCC to systemic treatment in advanced HCC. The potential of Ang-2 as a diagnostic biomarker
is, despite its association with poor prognosis, however, less evident, since Ang-2 expression is already
upregulated in patients with chronic liver disease.
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